Cargando…
Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression
Our previous study indicated that colon cancer cells varied in sensitivity to pharmacological farnesoid X receptor (FXR) activation. Herein, we explore the regulatory mechanism of FXR in colorectal cancer (CRC) development and aim to design effective strategies of combined treatment based on the reg...
Autores principales: | Yu, Junhui, Yang, Kui, Zheng, Jianbao, Zhao, Pengwei, Xia, Jie, Sun, Xuejun, Zhao, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023572/ https://www.ncbi.nlm.nih.gov/pubmed/35449124 http://dx.doi.org/10.1038/s41419-022-04745-5 |
Ejemplares similares
-
Correction: Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression
por: Yu, Junhui, et al.
Publicado: (2023) -
Activation of FXR promotes intestinal metaplasia of gastric cells via SHP-dependent upregulation of the expression of CDX2
por: Zhou, Haining, et al.
Publicado: (2018) -
Bile acids promote gastric intestinal metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway
por: Yu, Jun-Hui, et al.
Publicado: (2019) -
Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
por: Nijmeijer, Rian M., et al.
Publicado: (2011) -
Targeted CDX2 expression inhibits aggressive phenotypes of colon cancer cells in vitro and in vivo
por: Zheng, Jianbao, et al.
Publicado: (2017)